Amgen Delays Phase III Trials Of AMG-706 Due To Cholecystitis Concerns
This article was originally published in The Pink Sheet Daily
Interim data from Phase II gastrointestinal stromal cancer trials showed 2%-3% of patients developed cholecystitis.
You may also be interested in...
Amgen's panitumumab has an estimated mid-September user fee date under FDA priority review for metastatic colorectal cancer patients failing prior chemotherapy, the company announced June 12
Cetuximab was approved March 1 for treatment of advanced head and neck cancer.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.